ALK gene | sciencenewsnet.in

Breaking News

MD Anderson launches Institute for Cell Therapy Discovery & Innovation to deliver transformational new therapies

Key Pathway Leading to Neurodegeneration in Early Stages of ALS Identified

Deep ocean clues to a million-year-old Ice Age puzzle revealed in new study

Deep Vein Thrombosis Affects 3% of Central Venous Catheters in NICU Patients

Maintaining “Good” Care: An Articulation Work Perspective on Organizational Ethics in the Healthcare Sector

Turning a Blind Eye to Team Members’ Unethical Behavior: The Role of Reward Systems

Number of Whooping Cough Cases on Rise Nationally

Religion in Family Firms: A Socioemotional Wealth Perspective on Top-Level Executives with Perceived Religiosity

Appealing to voters through podcasts, expert explains advantages

United Nations ratifies framework to protect people on cash apps

08 Nov, 2024

Researchers Show Lorlatinib is Safe and Effective for Patients with ALK-Driven Relapsed/Refractory High-Risk Neuroblastoma

April 3, 2023 sarah JonasResearch Results

In a significant step for the treatment of neuroblastoma, an international group of researchers led by Children’s Hospital of Philadelphia (CHOP), Winship Cancer Institute of Emory University and the New Approaches to Neuroblastoma Therapy (NANT) Consortium has shown that the targeted therapy lorlatinib is safe and effective in treating high-risk neuroblastoma.